Cambridge scientists have received two of the biggest funding grants ever awarded by Cancer Research UK, with the charity set to invest £40 million over the next five years in two ground-breaking research projects in the city.
Researchers in Cambridge are set to receive a £5m Cancer Research UK’s Catalyst Award to improve the early detection of cancers in GP surgeries. The CanTest team, led by Dr Fiona Walter from the University of Cambridge, will work with researchers in three UK sites and across the globe on a five year project that will help GPs to detect cancers in a primary care setting, enabling patients to benefit from innovative approaches and new technologies, and reducing the burden of referrals.
Cambridge scientists are set to receive a major cash injection from Cancer Research UK, which has announced plans to invest over £41 million over the next five years at the Cancer Research UK Cambridge Centre, one of the University of Cambridge’s Strategic Research Initiatives. The funding will help support ground-breaking work as part of the development of a unique chain of research hubs around the UK.
Two Cambridge institutes have today been confirmed as major research centres by biomedical research charity Wellcome, receiving continued support for a further five years. The centres will be co-funded by Cancer Research UK (CRUK) and the Medical Research Council (MRC) respectively.
A weight loss condition that affects patients with cancer has provided clues as to why cancer immunotherapy – a new approach to treating cancer by boosting a patient’s immune system – may fail in a substantial number of patients.
The next generation of imaging technology, newly installed at the University of Cambridge, will give researchers an unprecedented view of the human body – in particular of the myriad connections within our brains and of tumours as they grow and respond to treatment – and could pave the way for development of treatments personalised for individual patients.
Britons eating a Mediterranean diet could lower their risk of developing heart disease and stroke, according to research published in the open access journal BMC Medicine.
Researchers have identified the role that a four-stranded version of DNA may play in the role of cancer progression, and suggest that it may be used to develop new targeted cancer therapies.
Tailored, targeted treatment for patients with oesophageal cancer could be developed after scientists discovered that the disease can be classified into three different subtypes